- Shanghai Pharma reported a net income of 2.94 billion yuan for the first half of the year.
- The company’s operating revenue reached 139.4 billion yuan.
- Earnings per share (EPS) stood at 79 RMB cents.
- Selling expenses for the period were 6.57 billion yuan.
- Research and Development (R&D) expenses amounted to 1.11 billion yuan.
- Analyst consensus includes 12 buy ratings, 0 hold ratings, and 1 sell rating.
A look at Shanghai Pharmaceuticals Holding Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
“`html
Based on the Smartkarma Smart Scores, Shanghai Pharmaceuticals Holding is positioned favorably for long-term growth and stability. With strong scores in Value and Dividend categories, the company demonstrates solid financial health and a commitment to providing returns to investors. Its Growth score, while slightly lower, still indicates potential for expansion in the future. Furthermore, Shanghai Pharmaceuticals Holding‘s respectable scores in Resilience and Momentum suggest a degree of stability and positive market sentiment surrounding the company.
Shanghai Pharmaceuticals Holding, a pharmaceutical manufacturer in China, shows promising long-term prospects as reflected in its Smartkarma Smart Scores. The company’s emphasis on value, dividends, and momentum positions it well for sustained success in the industry. With a diverse product portfolio that includes chemical and traditional Chinese medicines, as well as healthcare products, Shanghai Pharmaceuticals Holding is poised to capitalize on opportunities in the evolving healthcare market in China.
“`
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
